Human papillomavirus infection is very common among women under the age of 30. The newly infected human papillomavirus in women aged 30 and above is unlikely to change into persistent infection, but the infection found at this age may indicate persistent infection of human papillomavirus.
The most common types of high-risk infection among Chinese women are HPV 16, 18, 3 1, 33, 52 and 58.
The bivalent vaccine is aimed at human papillomavirus 16/ 18. Because of its special adjuvant, it can also prevent human papillomavirus 3 1, 33 and 45 infections at the same time. These five subtypes of human papillomavirus are related to more than 90% of cervical cancer.
From the public health point of view, the existing evidence proves that bivalent, tetravalent and nonavalent vaccines have no difference in immunogenicity, efficacy and effect in preventing HPV 16 and 18-related cervical cancer, and all three vaccines can help prevent most cervical cancers.
The bivalent vaccine is aimed at HPV 16/ 18. Epidemiology in China found that human papillomavirus1618 caused 84.5% of cervical squamous cell carcinoma in Chinese mainland.
The tetravalent vaccine can not only target human papillomavirus 16/ 18, but also prevent human papillomavirus 6 and 1 1. Human papillomavirus types 6 and 1 1 do not cause cervical cancer, but are related to more than 90% condyloma acuminatum.
The nine-valent vaccine is targeted at HP V6/1116/18/31/33/45/52/58. These subtypes of human papillomavirus are associated with 93% of cervical cancer.
At present, the degree of cross-protection of nine-valent vaccine is not clear.
From the overall protection rate of cervical cancer, there is not much difference between the three vaccines currently on the market, and the nine-valent vaccine is not an upgraded version of the bivalent and tetravalent vaccines.
After vaccination with bivalent or tetravalent vaccine, there is no need to replant the nine-valent vaccine!